Delisting riskPopularity #4,349
Jupiter Neurosciences (JUNS)
Develops CNS drug candidates and sells Nugevia longevity supplements.
$2.92
vs last close−0.06 (−2.01%)
Something off on this page? Send us feedback.
Next report
Dec 2, 26
estimated · in 70 days
EPS estimate
−$3.75
Revenue estimate
$602.0K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Dec '25Apr '26May '26Aug '26Dec '26
Reported−$3.76−$3.76−$5.26−$5.25−$5.61−$4.39−$5.06Pending
Estimate−$1.50−$2.26−$5.26−$6.00−$5.25−$3.75−$3.75−$3.75
Surprise−150.7%−66.4%0.0%+12.5%−6.9%−17.1%−34.9%—
RevenueReportedEstimate
Mar '25May '25Aug '25Dec '25Apr '26May '26Aug '26Dec '26
Reported————$21.8K$18.7K$24.2KPending
Estimate——$2.5M$75.0K$75.0K$225.0K$400.0K$602.0K
Surprise————−70.9%−91.7%−93.9%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$5.25 | — | — |
| Sep 2027 | −$5.25 | — | — |
| Jun 2027 | −$5.25 | — | — |
| Mar 2027 | −$3.75 | — | — |
| Dec 2026 | $14.25 | — | — |
| Dec 2026 | −$3.75 | — | — |
| Aug 2026 | −$3.75 | −$5.06 | −34.9% |
| May 2026 | −$3.75 | −$4.39 | −17.1% |
| Apr 2026 | −$5.25 | −$5.61 | −6.9% |
| Dec 2025 | −$6.00 | −$5.25 | +12.5% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Dec 2024 | |||
| Sep 2024 | |||
| Jun 2024 | |||
| Mar 2024 | |||
| Dec 2023 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$5.25 | — | — | $2.7M | — | — | — |
| Sep 2027 | −$5.25 | — | — | $2.0M | — | — | — |
| Jun 2027 | −$5.25 | — | — | $1.5M | — | — | — |
| Mar 2027 | −$3.75 | — | — | $1.2M | — | — | — |
| Dec 2026 | $14.25 | — | — | $10.9M | — | — | — |
| Dec 2, 2026 | −$3.75 | — | — | $602.0K | — | — | — |
| Aug 14, 2026 | −$3.75 | −$5.06 | −34.9% | $400.0K | $24.2K | −93.9% | −12.7% |
| May 21, 2026 | −$3.75 | −$4.39 | −17.1% | $225.0K | $18.7K | −91.7% | +32.1% |
| Apr 3, 2026 | −$5.25 | −$5.61 | −6.9% | $75.0K | $21.8K | −70.9% | −7.5% |
| Dec 22, 2025 | −$6.00 | −$5.25 | +12.5% | $75.0K | — | — | 0.0% |
| Aug 18, 2025 | |||||||
| May 15, 2025 | |||||||
| Mar 28, 2025 | |||||||
| Dec 23, 2024 | |||||||
| Sep 4, 2024 | |||||||
| Jun 30, 2024 | |||||||
| Mar 31, 2024 | |||||||
| Dec 31, 2023 | |||||||
| Sep 30, 2023 | |||||||
| Jun 30, 2023 | |||||||
| Mar 31, 2023 | |||||||
| Jun 30, 2022 | |||||||
| Mar 31, 2022 | |||||||
| Dec 31, 2021 | |||||||
| Sep 30, 2021 | |||||||
| Jun 30, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Sep 30, 2020 |